摘要
目的考察河南省内科医生吡非尼酮胶囊的用药情况和态度,为规范用药和制定指南共识提供依据。方法2023年6月11日—14日,通过电子问卷方式,对河南省二级及三级医院内科、呼吸医生进行调查。结果共回收有效问卷333份。吡非尼酮胶囊临床应用最多的指征是特发性肺纤维化(IPF)。关于IPF、进展性肺纤维化、纤维化型间质性肺病、结缔组织病相关间质性肺病(CTD-ILD)使用吡非尼酮胶囊,同意度平均得分为4.55、4.25、4.17、3.82分。关于IPF患者中使用抗纤维化治疗的比例,选择0~30%、30%~50%、50%~70%、70%以上的比例分别为36.0%、19.2%、17.4%、27.3%。69.4%认为大多数患者能耐受吡非尼酮胶囊的不良反应。结论对不同疾病中吡非尼酮胶囊应用指征、方法及不良反应处理,医生意见具有异质性,需制定相关共识进一步规范。
Objective To investigate the attitude and knowledge of physicians in Henan Province in prescribing pirfenidone capsules.Methods From June 11 to 14,2023,an electronic questionnaire was developed and used in the on-line investigation with doctors from the internal or respiratory departments of second-and third-level hospitals in Henan Province.Results A total of 333 valid questionnaires were collected.The primary indications of pirfenidone capsules include idiopathic pulmonary fibrosis(IPF).With regard to the use of pirfenidone capsules in IPF,progressive pulmonary fibrosis,fibrotic interstitial lung disease,connective tissue disease-associated interstitial lung disease(CTD-ILD),the average score of consent was 4.55,4.25,4.17,3.82.About the proportion of patients with IPF using antifibrotic therapy,the proportion choosing 0-30%,30%-50%,50%-70%,and more than 70%was 36.0%,19.2%,17.4%,and 27.3%,respectively.It was found that 69.4%believed that the majority of patients can tolerate the adverse reactions of pirfenidone capsules.Conclusion Considerable heterogeneity lies in the indications,methods,and adverse reaction management of pirfenidone capsules in physicians,and consensus guidelines are in need for further standardization of its use.
作者
臧凯旋
汪铮
陈闪闪
张晓菊
张国俊
余学庆
毛毅敏
张祎捷
ZANG Kaixuan;WANG Zheng;CHEN Shanshan;ZHANG Xiaoju;ZHANG Guojun;YU Xueqing;MAO Yimin;ZHANG Yijie(Zhengzhou University People’s Hospital,Zhengzhou 450003,China;Department of Respiratory and Critical Care Medicine,Henan Provincial People’s Hospital,Zhengzhou 450003,China;Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China;Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471003,China;Department of Respiratory and Critical Care Medicine,Huaihe Hospital of Henan University,Kaifeng 475000,China)
出处
《河南医学研究》
2025年第22期4052-4057,共6页
Henan Medical Research
基金
国家自然科学基金(81600047)
河南省医学科技攻关联合项目(LHGJ20190581)
河南省中青年卫生健康科技创新优秀青年人才培养项目(YXKC2020043)。
关键词
间质性肺疾病
特发性肺纤维化
吡非尼酮胶囊
适应证
不良反应
interstitial lung disease
idiopathic pulmonary fibrosis
pirfenidone capsule
indication
adverse effect
